NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production

Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor

(2012) Thérèse Keravis et al.   PLoS One

NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues

(2011) Issaka Yougbare et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane

(2011) A. Crilly et al.   ANNALS OF THE RHEUMATIC DISEASES

IκBβ is a positive and negative regulator of NF-κB activity during inflammation

(2010) Hideaki Kamata et al.   CELL RESEARCH

A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles

(2010) M L Budarf et al.   GENES AND IMMUNITY

Putting the lid on phosphodiesterase 4

(2010) Miles D Houslay et al.   NATURE BIOTECHNOLOGY

Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents

(2010) G. S. Cooper et al.   RHEUMATOLOGY

17,18-Epoxyeicosatetraenoic Acid Targets PPARγ and p38 Mitogen–Activated Protein Kinase to Mediate Its Anti-inflammatory Effects in the Lung

(2009) Caroline Morin et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Phosphodiesterase 3 and 4 Negatively Regulate Receptor Activator of Nuclear Factor-κB Ligand-Mediated Osteoclast Formation by Prostaglandin E2

(2009) A Long Sae Mi Noh et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Is there a future for small molecule drugs in the treatment of rheumatic diseases?

(2008) Joanna Stanczyk et al.   CURRENT OPINION IN RHEUMATOLOGY

Pamapimod, a Novel p38 Mitogen-Activated Protein Kinase Inhibitor: Preclinical Analysis of Efficacy and Selectivity

(2008) R. J. Hill et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis

(2008) Keith D Brown et al.   ARTHRITIS RESEARCH & THERAPY